TriLink BioTechnologies and Avantor® Collaborate to Enhance Nucleic Acid Solutions Across Europe
TriLink BioTechnologies Partners with Avantor to Expand Nucleic Acid Solutions in EMEA Region TriLink BioTechnologies® (TriLink), a global leader in providing life science reagents and services, has announced a strategic partnership with Avantor® Inc. (NYSE: AVTR), a key player in…
Dxcover Limited Secures New Funding and Expands Leadership Team to Drive Growth
Dxcover Secures $6.2 Million in Funding to Drive Growth and Expand Cancer Diagnostics Reach Dxcover Limited, a pioneering clinical-stage diagnostics company known for its cutting-edge multiomic spectral analysis technology (MOSA-Dx™) for the early detection of solid tumor cancers, has announced…
Inhalon Biopharma to Begin Human Trials for First Inhaled Antibody Treatment for RSV
Inhalon Biopharma Advances Breakthrough Inhaled Antibody Treatment for RSV, Targets 2026 Human Trials Inhalon Biopharma, Inc., a clinical-stage company pioneering innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the development of its first-in-class inhaled antibody…
Pfizer’s BRAFTOVI® Combo Boosts Survival in Phase 3 BREAKWATER Trial
Pfizer’s BRAFTOVI® Combo Boosts Survival in Phase 3 BREAKWATER Trial Pfizer Inc. (NYSE: PFE) has announced promising results from the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin)…
Avanzanite Bioscience Proudly Names New Chief Financial Officer
Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company dedicated to advancing life-changing medicines for rare disease patients across Europe, has announced the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO). This strategic milestone strengthens the company’s…
Autoimmune AliveDx Launches MosaiQ AiPlex® CTDplus for Diagnosis
AliveDx has announced the receipt of IVDR-CE mark for its MosaiQ AiPlex® CTDplus multiplex assay, a significant advancement in the diagnosis and management of Systemic Autoimmune Rheumatic Diseases (SARDs). This multiplex assay enables a syndromic approach, streamlining laboratory workflow while…
CHMP Recommends Subcutaneous RYBREVANT® for Advanced EGFR-Mutated NSCLC Treatment
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the Subcutaneous European Medicines Agency (EMA) has issued a positive recommendation for an extension of marketing authorization for…
Health Care Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care
Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care Gail L. Lamoureux, BS, a dedicated and accomplished professional in the health care industry, has been honored with inclusion in Marquis Who’s Who. This Marquis prestigious recognition…
Vertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England
Vertex Pharmaceuticals Announces Landmark Reimbursement Agreement with NHS England, Expanding Access to CASGEVY® for Sickle Cell Disease Patients Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has revealed a significant milestone in the fight against sickle cell disease (SCD) with the announcement of…
Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan
TWYMEEG® Sales Performance and Forecast Update Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan A clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases characterized by metabolic pathophysiology, including metabolic…
BrightHeart Unveils Groundbreaking AI Results at SMFM 2025 Pregnancy Meeting, Transforming Prenatal Care
BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, recently presented two groundbreaking studies at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, which took place in Aurora, Colorado, on January 30th. These presentations,…
KORU Medical Systems Partners on Phase III Clinical Trial for New Nephrology Drug Indication
KORU Medical Systems Announces Strategic Collaboration for Phase III Clinical Trial on Expanded Drug Indication for Rare Renal Disorder KORU Medical Systems (NASDAQ: KRMD), a prominent medical technology company focused on innovative, patient-centric large volume subcutaneous infusion solutions, has announced…